RT Journal Article
SR Electronic
T1 BNT162b2 Vaccine Induces Divergent B cell responses to SARS-CoV-2 S1 and S2
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.07.20.21260822
DO 10.1101/2021.07.20.21260822
A1 Brewer, R. Camille
A1 Ramadoss, Nitya S.
A1 Lahey, Lauren J.
A1 Robinson, William H.
A1 Lanz, Tobias V.
YR 2021
UL http://medrxiv.org/content/early/2021/07/22/2021.07.20.21260822.abstract
AB The first ever messenger RNA (mRNA) vaccines received emergency approvals in December 2020 and are highly protective against SARS-CoV-21–3. However, the contribution of each dose to the generation of antibodies against SARS-CoV-2 spike (S) protein and the degree of protection against novel variants, including delta, warrant further study. Here, we investigated the B cell response to the BNT162b2 vaccine by integrating repertoire analysis with single-cell transcriptomics of B cells from serial blood collections pre- and post-vaccination. The first vaccine dose elicits highly mutated IgA+ plasmablasts against the S protein subunit S2 at day 7, suggestive of recall of a memory B cell response generated by prior infections with heterologous coronaviruses. On day 21, we observed minimally-mutated IgG+ activated switched memory B cells targeting the receptor binding domain (RBD) of the S protein, likely representing a primary response derived from naïve B cells. The B cell response against RBD is specifically boosted by the second vaccine dose, and encodes antibodies that potently neutralize SARS-CoV-2 pseudovirus and partially neutralize novel variants, including delta. These results demonstrate that the first vaccine dose activates a non-neutralizing recall response predominantly targeting S2, while the second vaccine dose is vital to boosting neutralizing anti-S1 RBD B cell responses.Competing Interest StatementW.H.R. is a founder, member of the board of directors, and consultant to Atreca, Inc. Funding StatementThis work was supported by T32 AI007290-35 to R.C.B.; National Science Foundation Graduate Research Fellowship to R.C.B; the German Research Foundation (DFG, LA3657/1) to T.V.L.; NIH R01 AR063676 and U19 AI110491 to W.H.R.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:All studies were approved by the Institutional Review Board of Stanford University (IRB-3780), and the studies complied with the relevant ethical regulations.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe raw sequencing data will be uploaded in the GEO database before final publication.